Una puesta al día: diagnóstico y tratamiento | 07 ABR 19

Herpes zóster

Una enfermedad provocada por la reactivación del virus varicela zóster
Autor: Phuc Le, Michael Rothberg BMJ 2019;364:k5095
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Gnann JWJr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002;347:340-6.10.1056/NEJMcp013211 12151472

2 Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014;4:e004833.10.1136/bmjopen-2014-004833 24916088

3 Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995;155:1605-9. 10.1001/archinte.1995.00430150071008 7618983ç

4 Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005;20:748-53.10.1111/j.1525-1497.2005.0150.x 16050886

5 Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995;172:706-12. 10.1093/infdis/172.3.706 7658062

6 Yanni EA, Ferreira G, Guennec M, etal . Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open 2018;8:e020528.10.1136/bmjopen-2017-020528 29880565

7 Fleming DM, Cross KW, Cobb WA, Chapman RS. Gender difference in the incidence of shingles. Epidemiol Infect 2004;132:1-5. 10.1017/S0950268803001523 149795828 Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995;171:701-4.10.1093/infdis/171.3.701 7876622

9 Buchbinder SP, Katz MH, Hessol NA, etal . Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-6. 10.1093/infdis/166.5.1153 1308664

10 Alliegro MB, Dorrucci M, Pezzotti P, etal. Herpes zoster and progression to AIDS in a cohort of individuals who seroconverted to human immunodeficiency virus. Italian HIV Seroconversion Study. Clin Infect Dis 1996;23:990-5. 10.1093/clinids/23.5.990 8922791

11 Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995;21:370-5.10.1093/clinids/21.2.370 8562746

12 Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006;4:1483-90.10.1016/j.cgh.2006.09.019 17162240

13 Smith JB, Fenske NA. Herpes zoster and internal malignancy. South Med J 1995;88:1089-92. 10.1097/00007611-199511000-00001 7481976

14 Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002;20:2500-7. 10.1016/S0264-410X(02)00180-9 12057605

15 Kawai K, Yawn BP, Wollan P, Harpaz R. ncreasing incidence of herpes zoster over a 60-year period from a population-based study. Clin Infect Dis 2016;63:221-6.10.1093/cid/ciw296 27161774

16 Hales CM, Harpaz R, Joesoef MR, Bialek SR. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann Intern Med 2013;159:739-45.10.7326/0003-4819-159-11-201312030-00006 24297190

17 Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007;135:908-13.10.1017/S0950268807007893 17291380.

18 Brisson M, Edmunds WJ, Law B, etal . Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001;127:305-14.10.1017/S0950268801005921 11693508

19 Toyama N, Shiraki KSociety of the Miyazaki Prefecture Dermatologists. Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009;81:2053-8.10.1002/jmv.21599 19856466

20 Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001;32:1481-6.10.1086/320169 11317250

21 Dworkin RH, Johnson RW, Breuer J, etal . Recommendations for the management of herpes zoster. Clin Infect Dis 2007;44(Suppl 1):S1-26. 10.1086/510206 17143845

22 Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004;39:342-8.10.1086/421942 15307000

23 Roxas M. Herpes zoster and postherpetic neuralgia: diagnosis and therapeutic considerations. Altern Med Rev 2006;11:102-13.16813460

24 Gilden DH, Wright RR, Schneck SA, Gwaltney JMJr, Mahalingam R. Zoster sine herpete, a clinical variant. Ann Neurol 1994;35:530-3. 10.1002/ana.410350505 8179298

25 Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342:635-45. 10.1056/NEJM200003023420906 10699164

26 Dahl H, Marcoccia J, Linde A. Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. J Clin Microbiol 1997;35:347-9.9003593

27 Sauerbrei A, Eichhorn U, Schacke M, Wutzler P. Laboratory diagnosis of herpes zoster. J Clin Virol 1999;14:31-6. 10.1016/S1386-6532(99)00042-6 10548128

28 Opstelten W, Zaal MJ. Managing ophthalmic herpes zoster in primary care. BMJ 2005;331:147-51. 10.1136/bmj.331.7509.147 16020856

29 Harding SP, Lipton JR, Wells JC. Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement. Br J Ophthalmol 1987;71:353-8.10.1136/bjo.71.5.353 3495293

30 Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician 2002;66:1723-30.12449270

31 Oxman MN, Levin MJ, Johnson GR, etal. Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84. 10.1056/NEJMoa051016 15930418

32 Tyring S, Barbarash RA, Nahlik JE, etal. Collaborative Famciclovir Herpes Zoster Study Group. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:89-96. 10.7326/0003-4819-123-2-199507150-00002 7778840

33 Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53. 10.1128/AAC.39.7.1546 7492102

34 Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996;22:341-7. 10.1093/clinids/22.2.341 8838194

35 Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 1997;157:909-12. 10.1001/archinte.1997.00440290095010 9129551

36 Tyring SK, Beutner KR, Tucker BA, AndersonWC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9:863-9.10.1001/archfami.9.9.863 11031393

37 Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. Reg Anesth Pain Med 2004;29:454-61.15372391

38 Wolff RF, Bala MM, Westwood M, Kessels AG, Kleijnen J. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review. Acta Neurol Scand 2011;123:295-309.10.1111/j.1600-0404.2010.01433.x 21039364

39 Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000;87:121-9. 10.1016/S0304-3959(00)00230-X 10924805

40 Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998;280:1837-42.10.1001/jama.280.21.1837 9846778

41 Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41. 10.1212/WNL.50.6.1837 9633737

42 Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989;21:265-70.10.1016/S0190-9622(89)70171-7 2768576

43 Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999;80:533-8. 10.1016/S0304-3959(98)00244-9 10342414

44 Backonja M, Wallace MS, Blonsky ER, etal. NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7:1106-12.10.1016/S1474-4422(08)70228-X 18977178

45 Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;1:CD007393.28085183

46 Irving GA, Backonja MM, Dunteman E, etal. NGX-4010 C117 Study Group. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011;12:99-109.10.1111/j.1526-4637.2010.01004.x 21087403

47 Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 2010;11:972-82.10.1016/j.jpain.2010.01.270 20655809

48 Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J NeurolNeurosurg Psychiatry 2010;81:1372-3. 10.1136/jnnp.2008.144964 20543189ç

49 Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Curr Med Res Opin 2010;26:2411-9.10.1185/03007995.2010.516142 20812792

50 Wiffen PJ, Derry S, Bell RF, etal . Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017;6:CD007938.28597471

51 Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract 2010;11:85. 10.1186/1471-2296-11-85 21054853

52 Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med 2009;24:178-88.10.1007/s11606-008-0877-5 19089502

53 Dooling KL, Guo A, Patel M, etal . Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep 2018;67:103-8. 10.15585/mmwr.mm6703a5 29370152

54 Kim DK, Riley LE, Hunter P. Advisory Committee on Immunisation practices recommended immunisation schedule for adults aged 19 years or older—United States, 2018. MMWR Morb Mortal Wkly Rep 2018;67:158-60. 10.15585/mmwr.mm6705e3 29420462

55 Morrison VA, Johnson GR, Schmader KE, etal. Shingles Prevention Study Group. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015;60:900-9.10.1093/cid/ciu918 25416754

56 Lal H, Cunningham AL, Godeaux O, etal. ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087-96.10.1056/NEJMoa1501184 25916341

57 Tricco AC, Zarin W, Cardoso R, etal . Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: systematic review and network meta-analysis. BMJ 2018;363:k4029. 10.1136/bmj.k4029 30361202

58 Chlibek R, Smetana J, Pauksens K, etal . Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 2014;32:1745-53.10.1016/j.vaccine.2014.01.019 24508036

59 Cunningham AL, Lal H, Kovac M, etal. ZOE-70 Study Group. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019-32.10.1056/NEJMoa1603800 27626517

60 Grupping K, Campora L, Douha M, etal . Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis 2017;216:1343-51.10.1093/infdis/jix482 29029122

61 Schwarz TF, Aggarwal N, Moeckesch B, etal . Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis 2017;216:1352-61. 10.1093/infdis/jix481 29029224

62 Shimabukuro TT, Miller ER, Strikas RA, etal . Notes from the field: vaccine administration errors involving recombinant zoster vaccine—United States, 2017-2018. MMWR Morb Mortal Wkly Rep 2018;67:585-6.10.15585/mmwr.mm6720a4 29795075

63 Le P. Which shingles vaccine for older adults?BMJ 2018;363:k4203. 10.1136/bmj.k4203 30361204 Published



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Contenidos relacionados
Los editores le recomiendan continuar con las siguientes lecturas: